EMA Using Real World Data To Assess Safety Of COVID-19 Vaccines
Oxford/AstraZeneca Vaccine Renamed Vaxzevria In The EU
Executive Summary
The EMA is investigating possible links between the three COVID-19 vaccines currently being used in Europe and cases of thrombotic events. It is also planning safety studies in targeted populations.
You may also be interested in...
Coronavirus Notebook: EU Leaders Cool On Vaccine Export Plans, EMA OKs New Production Plants
Sputnik V is to be manufactured by a plant in Serbia, and the UK has set up a new health security agency to deal with emerging future threats.
Europe To Resume AZ Vaccine Use After Safety Review, But Confidence Knocked
The EMA’s conclusions are in line with those of the UK regulator and the World Health Organization, but EU countries’ stop-start decisions will have done nothing to boost the public’s trust in the vaccine.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.